ME02185B - Anti-il-6 antitela, preparati, postupci pripreme i upotrebe - Google Patents

Anti-il-6 antitela, preparati, postupci pripreme i upotrebe

Info

Publication number
ME02185B
ME02185B MEP-2015-100A MEP10015A ME02185B ME 02185 B ME02185 B ME 02185B ME P10015 A MEP10015 A ME P10015A ME 02185 B ME02185 B ME 02185B
Authority
ME
Montenegro
Prior art keywords
drug
endif
seq
amino acid
acid sequence
Prior art date
Application number
MEP-2015-100A
Other languages
English (en)
Inventor
Debra Gardner
David M Knight
Michael W Lark
Bailin Liang
David J Shealy
Xiao-Yu R Song
Vedrana Stojanovic-Susulic
Raymond W Sweet
Susan H Tam
Sheng-Jiun Wu
Jing Yang
David Matthew Marquis
Eric Michael Smith
Alain Philippe Vasserot
Yan Chen
Original Assignee
Janssen Biotech Inc
Applied Molecular Evolution Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Applied Molecular Evolution Inc filed Critical Janssen Biotech Inc
Publication of ME02185B publication Critical patent/ME02185B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)

Description

LISTING SEKVENCI
 
[0310]
 
<110> "Centocor, Inc. Applied Molecular Evolution, Inc."
 
<120> Anti-IL-6 Antitela Compozicije, Metodi i Upotrebe
 
<130> CEN5094 PCT
 
<140> PCT/US2006/016457
<141> 2006-APR-28
 
<150> 60/676, 498
<151> 2005-APR-29
 
<150> 60/677,319
<151> 2005-MAJ-03
 
<160> 138
 
<170> Fast SEK za Windows Verziju 4.0
 
<210> 1
<211> 10
<212> PRT
<213> Homo sapiens
 
<400> 1
 
<210> 2
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 2
agtgccagcc atagtgtaag ttacatgtac 30
 
<210> 3
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 3
 
 
 
 
 
<210> 4
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 4
agtgccagca ttagtgtaag ttacatgtac 30
 
 
<210> 5
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 5
 
 
 
 
 
<210> 6
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 6
agtgcccggt caagtgtaag ttacatgtac 30
 
<210> 7
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 7
 
 
 
 
 
<210> 8
<211> 30
<212> DNA
<213> Homo sapiens
 
 
 
 
<400> 8
agtgccagct atagtgtaag ttacatgtac 30
 
 
<210> 9
<211> 10
<212> PRT
<213> Homo sapiens
 
<400> 9
 
 
 
 
 
<210> 10
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 10
agtgccagct caagtgtatt ttacatgtac 30
 
 
<210> 11
<211> 10
<212> PRT
<213> Homo sapiens
 
<400> 11
 
 
 
 
 
<210> 12
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 12
agtggcagct catatgtaag ttacatgtac 30
 
<210> 13
<211> 10
<212> PRT
<213> Homo sapiens
 
<400> 13
 
 
 
 
 
 
 
<210> 14
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 14
agtgccctgt caagtgtaag ttacatgtac 30
 
 
<210> 15
<211> 10
<212> PRT
<213> Homo sapiens
<400> 15
 
 
 
<210> 16
<211> 30
<212> DNA
<213> Homo sapiens
 
<400> 16
agtgccagct caagtgtaag ttacatgtac 30
 
 
<210> 17
<211> 7
<212> PRT
<213> Homo sapiens
 
 
<400> 17
 
 
 
 
<210> 18
<211> 21
<212> DNA
<213> Homo sapiens
 
 
<400> 18
gacttttcca acctggcttc t 21
 
<210> 19
<211> 7
<212> PRT
<213> Homo sapiens
 
 
 
 
 
 
 
<400> 19
 
 
 
 
<210> 20
<211> 21
<212> DNA
<213> Homo sapiens
 
<400> 20
gacctgtcca acctggcttc t 21
 
 
<210> 21
<211> 7
<212> PRT
<213> Homo sapiens
 
<400> 21
 
 
 
 
<210> 22
<211> 21
<212> DNA
<213> Homo sapiens
 
<400> 22
gacatgtcca acctggcttc t 21
 
<210> 23
<211> 7
<212> PRT
<213> Homo sapiens
 
 
<400> 23
 
 
 
 
<210> 24
<211> 21
<212> DNA
<213> Homo sapiens
 
 
<400> 24
gacacatcca acctgacgtc t 21
 
<210> 25
<211> 7
<212> PRT
<213> Homo sapiens
 
 
<400> 25
 
 
 
 
<210> 26
<211> 21
<212> DNA
<213> Homo sapiens
 
<400> 26
gacacatccg agctggcttc t 21
 
<210> 27
<211> 7
<212> PRT
<213> Homo sapiens
 
 
<400> 27
 
 
 
 
 
<210> 28
<211> 21
<212> DNA
<213> Homo sapiens
 
<400> 28
gacacatcca acctggcttc t 21
 
 
<210> 29
<211> 9
<212> PRT
<213> Homo sapiens
 
 
<400> 29
 
 
 
 
 
 
<210> 30
<211> 27
<212> DNA
<213> Homo sapiens
 
 
<400> 30
atgcagtgga gtggttaccc atacacg 27
 
 
<210> 31
 
 
 
 
 
<211> 9
<212> PRT
<213> Homo sapiens
 
 
<400> 31
 
 
 
 
 
 
<210> 32
<211> 27
<212> DNA
<213> Homo sapiens
 
 
 
<400> 32
tgtcagtgga gtggttaccc atacacg 27
 
<210> 33
<211> 9
<212> PRT
<213> Homo sapiens
 
 
<400> 33
 
 
 
 
 
 
 
<210> 34
<211> 27
<212> DNA
<213> Homo sapiens
 
 
<400> 34
tctgtgtgga gtggttaccc atacacg 27
 
 
<210> 35
<211> 9
<212> PRT
<213> Homo sapiens
 
 
<400> 35
 
 
 
 
 
<210> 36
<211> 27
<212> DNA
<213> Homo sapiens
 
<400> 36
tctcagtgga gtggttaccc atacacg 27
<210> 37
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 37
 
 
 
 
 
 
<210> 38
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 38
ggattcacct ttagtagctt tgccctttct 30
 
 
<210> 39
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 39
 
 
 
 
<210> 40
<211> 30
<212> DNA
<213> Homo sapiens
 
 
 
 
 
<400> 40
ggattcacct ttagtccttt tgccatgtct 30
 
 
<210> 41
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 41
 
 
 
 
 
 
<210> 42
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 42
ggattccagt ttagtagctt tgccatgtct 30
 
<210> 43
<211> 10
<212> PRT
<213> Homo sapiens
 
 
 
 
 
<400> 43
 
 
 
 
 
 
<210> 44
<211> 30
<212> DNA
<213> Homo sapiens
 
<400> 44
ggattcacca ctagtagctt tgccatgtct 30
 
 
<210> 45
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 45
 
 
 
 
 
 
<210> 46
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 46
ggattccagt ttagtccttt tgccatgtct 30
 
 
<210> 47
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 47
 
 
 
 
 
 
<210> 48
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 48
ggattcacct ttagtagctt tgccatgtct 30
 
 
<210> 49
<211> 17
<212> PRT
<213> Homo sapiens
 
 
 
<400> 49
 
 
 
 
 
 
 
<210> 50
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 50
aaagcgagta gtggtgggag ttacacctac tatcctgaca ctgtgacggg c 51
 
<210> 51
<211> 17
<212> PRT
<213> Homo sapiens
 
 
 
<400> 51
 
 
 
 
 
 
<210> 52
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 52
aaaattagta gtggtgggag ttacgagtac tatcctgaca ctgtgacggg c 51
 
 
<210> 53
<211> 17
<212> PRT
<213> Homo sapiens
 
 
 
<400> 53
 
 
 
 
 
 
 
<210> 54
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 54
aaaattagta gtggtgggag ttactattac tatcctgaca ctgtgacggg c 51
 
 
<210> 55
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 55
 
 
 
 
 
 
 
<210> 56
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 56
aaaattagta gtggtgggag ttggacctac tatcctgaca ctgtgacggg c 51
 
 
<210> 57
<211> 17
<212> PRT
<213> Homo sapiens
 
<400> 57
 
 
 
 
 
 
 
 
<210> 58
<211> 51
<212> DNA
<213> Homo sapiens
 
<400> 58
aaaattagtc cgggtgggag ttacacctac tatcctgaca ctgtgacggg c 51
 
 
<210> 59
<211> 17
<212> PRT
<213> Homo sapiens
 
<400> 59
 
 
 
 
 
 
 
<210> 60
<211> 51
<212> DNA
<213> Homo sapiens
 
<400> 60
aaaattagtc cgggtgggag ttggacctac tattctgaca ctgtgacggg c 51
 
<210> 61
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 61
 
 
 
 
 
 
<210> 62
<211> 51
<212> DNA
<213> Homo sapiens
 
 
 
<400> 62
aaaattagta gtggtgggag ttacacctac tatcctgaca ctgtgacggg c 51
 
<210> 63
<211> 17
<212> PRT
<213> Homo sapiens
 
<400> 63
 
 
 
 
 
 
 
<210> 64
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 64
aaaattagta gtggtgggag ttacacctac tttcctgaca ctgtgacggg c 51
 
<210> 65
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 65
 
 
 
 
 
 
 
<210> 66
<211> 51
<212> DNA
<213> Homo sapiens
<400> 66
aaaattagta gtggtgggag ttacacctac tatcctgaca ctgtggctgg c 51
 
 
 
<210> 67
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 67
 
 
 
 
 
 
<210> 68
<211> 51
<212> DNA
<213> Homo sapiens
 
<400> 68
aaaattagta gtggtgggag ttacacctac tatgatgaca ctgtgacggg c 51
 
<210> 69
<211> 17
<212> PRT
<213> Homo sapiens
 
<400> 69
 
 
 
 
 
 
 
<210> 70
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 70
aaaattagta gtggtgggag ttacacctac tattctgaca ctgtgacggg c 51
 
 
<210> 71
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 71
 
 
 
 
 
 
<210> 72
<211> 51
<212> DNA
<213> Homo sapiens
 
<400> 72
aaaattagta gtggtgggag ttacacctac tatcctgaca ctgtgacgcc g 51
 
<210> 73
<211> 17
<212> PRT
<213> Homo sapiens
 
 
 
 
 
 
<400> 73
 
 
 
 
 
 
<210> 74
<211> 51
<212> DNA
<213> Homo sapiens
<400> 74
aaaattagta gtggtgggag ttacacctac tatcctgaca ctgatacggg c 51
 
 
<210> 75
<211> 17
<212> PRT
<213> Homo sapiens
 
 
 
 
<400> 75
 
 
 
 
 
 
 
 
 
<210> 76
<211> 51
<212> DNA
<213> Homo sapiens
 
<400> 76
aaaattagtc cgggtgggag ttacacctac tattctgaca ctgtgacggg c 51
 
<210> 77
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 77
 
 
 
 
 
 
<210> 78
<211> 51
<212> DNA
<213> Homo sapiens
 
 
<400> 78
aaaattagtc cgggtgggag ttggacctac tatgatgaca ctgtgacggg c 51
 
<210> 79
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 79
 
 
 
 
<210> 80
<211> 30
<212> DNA
<213> Homo sapiens
 
<400> 80
cagttatggg ggtcgtatgc tcttgactac 30
 
<210> 81
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 81
 
 
 
 
 
 
<210> 82
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 82
cagttatggg ggtactatgc tcttgacacg 30
 
 
<210> 83
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 83
 
 
 
 
 
 
 
<210> 84
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 84
cagttatggg ggacttatgc tcttgactac 30
 
<210> 85
<211> 10
<212> PRT
<213> Homo sapiens
 
 
 
 
 
 
<400> 85
 
 
 
 
 
<210> 86
<211> 30
<212> DNA
<213> Homo sapiens
 
<400> 86
cagttatggg ggaattatgc tcttgactac 30
 
 
<210> 87
<211> 10
<212> PRT
<213> Homo sapiens
 
<400> 87
 
 
 
 
<210> 88
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 88
cagttatggg ggtactatgc tcttgacttt 30
 
<210> 89
<211> 10
<212> PRT
<213> Homo sapiens
 
 
 
<400> 89
 
 
 
 
 
 
 
<210> 90
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 90
cagttatggg ggtactatgc tcttgacatt 30
 
<210> 91
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 91
 
 
 
 
 
 
<210> 92
<211> 30
<212> DNA
<213> Homo sapiens
 
 
<400> 92
cagttatggg ggtactatgc tcttgactac 30
 
<210> 93
<211> 106
<212> PRT
<213> Homo sapiens
 
 
 
 
<400> 93
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 94
<211> 318
<212> DNA
<213> Homo sapiens
 
 
 
 
<400> 94
 
 
 
 
 
 
 
 
 
 
<210> 95
<211> 119
<212> PRT
<213> Homo sapiens
 
 
<400> 95
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 96
<211> 357
<212> DNA
<213> Homo sapiens
 
 
<400> 96
 
 
 
 
 
 
 
 
 
<210> 97
<211> 106
<212> PRT
<213> Homo sapiens
 
<400> 97
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 98
<211> 318
<212> DNA
<213> Homo sapiens
 
<400> 98
 
 
 
 
 
 
 
 
 
<210> 99
<211> 119
<212> PRT
<213> Homo sapiens
 
 
<400> 99
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 100
<211> 357
<212> DNA
<213> Homo sapiens
 
 
<400> 100
 
 
 
 
 
 
 
 
 
 
<210> 101
<211> 106
<212> PRT
<213> Homo sapiens
 
 
<400> 101
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 102
<211> 318
<212> DNA
<213> Homo sapiens
 
 
 
<400> 102
 
 
 
 
 
 
 
 
 
 
<210> 103
<211> 119
<212> PRT
<213> Homo sapiens
 
 
<400> 103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 104
<211> 357
<212> DNA
<213> Homo sapiens
 
 
<400> 104
 
 
 
 
 
 
 
 
 
<210> 105
<211> 23
<212> PRT
<213> Homo sapiens
 
<400> 105
 
 
 
 
 
 
 
 
 
<210> 106
<211> 15
<212> PRT
<213> Homo sapiens
 
 
<400> 106
 
 
 
 
 
 
<210> 107
<211> 32
<212> PRT
<213> Homo sapiens
 
 
<400> 107
 
 
 
 
 
 
 
<210> 108
<211> 10
<212> PRT
<213> Homo sapiens
 
 
<400> 108
 
 
 
 
<210> 109
<211> 25
<212> PRT
<213> Homo sapiens
 
 
<400> 109
 
 
 
 
 
 
 
<210> 110
<211> 14
<212> PRT
<213> Homo sapiens
 
 
<400> 110
 
 
 
 
<210> 111
<211> 32
<212> PRT
<213> Homo sapiens
 
 
<400> 111
 
 
 
 
 
 
 
 
<210> 112
<211> 11
<212> PRT
<213> Homo sapiens
 
<400> 112
 
 
 
 
 
 
<210> 113
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<400> 113
 
 
 
 
 
 
 
<210> 114
<211> 10
<212> PRT
<213> Homo sapiens
 
<400> 114
 
 
 
<210> 115
<211> 212
<212> PRT
<213> Homo sapiens
 
 
<400> 115
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 116
<211> 106
<212> PRT
<213> Homo sapiens
 
<400> 116
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 117
<211> 378
<212> DNA
<213> Homo sapiens
 
<400> 117
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 118
<211> 119
<212> PRT
<213> Homo sapiens
 
<400> 118
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 119
<211> 414
<212> DNA
<213> Homo sapiens
 
<400> 119
 
 
 
 
 
 
 
 
 
 
<210> 120
<211> 106
<212> PRT
<213> Homo sapiens
 
 
 
<400> 120
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 121
<211> 378
<212> DNA
<213> Homo sapiens
 
 
<400> 121
 
 
 
<210> 122
<211> 119
<212> PRT
<213> Homo sapiens
 
 
 
 
 
 
 
 
 
<400> 122
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 123
<211> 414
<212> DNA
<213> Homo sapiens
 
 
 
<400> 123
 
 
 
 
 
 
 
 
 
 
<210> 124
<211> 106
<212> PRT
<213> Homo sapiens
 
 
<400> 124
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 125
<211> 378
<212> DNA
<213> Homo sapiens
 
<400> 125
 
 
 
 
 
 
 
 
 
<210> 126
<211> 119
<212> PRT
<213> Homo sapiens
<400> 126
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 127
<211> 414
<212> DNA
<213> Homo sapiens
 
 
<400> 127
 
 
 
 
 
 
 
 
<210> 128
<211> 106
<212> PRT
<213> Homo sapiens
 
 
<400> 128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 129
<211> 378
<212> DNA
<213> Homo sapiens
 
<400> 129
 
 
 
 
 
 
 
<210> 130
<211> 119
<212> PRT
<213> Homo sapiens
 
 
 
<400> 130
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<210> 131
<211> 414
<212> DNA
<213> Homo sapiens
 
 
<400> 131
 
 
 
 
 
 
 
 
 
 
 
<210> 132
<211> 10
<212> PRT
<213> Homo sapiens
<220>
<221> nije sigurno
<222> (2) (3) (4) (5) (7)
<223> Gde Xaa može biti bilo koja od dvadeset prirodnih aminokiselina.
 
 
 
 
 
 
 
 
<400> 132
 
 
 
 
 
 
<210> 133
<211> 7
<212> PRT
<213> Homo sapiens
 
 
<220>
<221> nije sigurno
<222> (2) (4) (6)
<223> Gde Xaa može biti bilo koja od dvadeset prirodnih aminokiselina.
 
 
 
<400> 133
 
 
 
 
 
<210> 134
<211> 9
<212> PRT
<213> Homo sapiens
<220>
<221> nije sigurno
<222> (1)(2)
<223> Gde Xaa može biti bilo koja od dvadeset prirodnih aminokiselina.
 
<400> 134
 
 
 
 
 
 
<210> 135
<211> 10
<212> PRT
<213> Homo sapiens
<220>
<221> nije sigurno
<222> (3)(4)(6)(9)
<223> Gde Xaa može biti bilo koja od dvadeset prirodnih aminokiselina.
 
 
 
 
 
 
 
<400> 135
 
 
 
 
 
<210> 136
<211> 17
<212> PRT
<213> Homo sapiens
 
 
<220>
<221> nije sigurno
<222> (2) (4) (8) (9) (11) (12) (15) (16) (17)
<223> Gde Xaa može biti bilo koja od dvadeset prirodnih aminokiselina.
 
 
<400> 136
 
 
 
 
 
 
<210> 137
<211> 10
<212> PRT
<213> Homo sapiens
<220>
<221> nije sigurno
<222> (5)(10)
<223> Gde Xaa može biti bilo koja od dvadeset prirodnih aminokiselina.
 
 
 
 
 
 
<400> 137
 
<210> 138
 
<211> 9
<212> PRT
<213> Homo sapiens
<400> 138
 
 
 
 
 
 
 
 

Claims (20)

  1. <!--[if !supportLists]-->1. <!--[endif]-->Izolovano anti-IL-6 antitelo koje sadrži:(i) aminokiselinsku sekvencuvarijabilnog regiona lakog lanca označenu Identifikacionim brojem sekvence (SEQID NO): 101 i aminokiselinsku sekvencu varijabilnog regiona teškog lancaoznačenu kao SEQ ID NO: 103;(ii) aminokiselinsku sekvencuvarijabilnog regiona lakog lanca označenu kao SEQ ID NO: 124 i aminokiselinskusekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 126; (iii) aminokiselinsku sekvencuvarijabilnog regiona lakog lanca označenu kao SEQ ID NO: 116 i aminokiselinskusekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 118;(iv) aminokiselinsku sekvencuvarijabilnog regiona lakog lanca označenu kao SEQ ID NO: 120 i aminokiselinskusekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 122;(v) aminokiselinsku sekvencuvarijabilnog regiona lakog lanca označenu kao SEQ ID NO: 128 i aminokiselinskusekvencu varijabilnog regiona teškog lanca označenu kao SEQ ID NO: 130; ili(vi) aminokiselinsku sekvencu varijabilnog regiona lakog lanca označenukao SEQ ID NO: 97 i aminokiselinsku sekvencu varijabilnog regiona teškog lancaoznačenu kao SEQ ID NO: 99.
  2. 2. <!--[endif]-->Anti-IL-6 antitelo prema patentnom zahtevu 1, naznačeno time, što navedeno antitelo dovodi do promene najmanje jedne od aktivnosti bar jednog od anti-IL-6 polipeptida.
  3. 3. <!--[endif]-->Anti-IL-6 antitelo prema patentnim zahtevima 1 ili 2, naznačeno time, što EC50 vrednost navedenog antitela iznosi od oko 2.7 x 10-11 M ili manje.
  4. 4. <!--[endif]-->Anti-IL-6 antitelo prema patentnom zahtevu 3, naznačeno time, što EC50 vrednost iznosi oko 2.7 x 10-12 ili manje.
  5. 5. <!--[endif]-->Izolovan molekul nukleinske kiseline koji kodira najmanje jedno od anti-IL-6 antitela prema bilo kom od patentnih zahteva od 1 do 4.
  6. 6. <!--[endif]-->Izolovan vektor nukleinske kiseline koji sadrži molekul nukleinske kiseline prema patentnom zahtevu 5.
  7. 7. <!--[endif]-->Prokariotska ili eukariotska ćelija domaćin koja sadrži molekul nukleinske kiseline prema patentnom zahtevu 5.
  8. <!--[if !supportLists]-->8. <!--[endif]-->Ćelija domaćin prema patentnom zahtevu 7, naznačena time, što navedena ćelija domaćina označava ćeliju najmanje jedne od ćelijskih linija izabranih iz grupe koju čine COS-1, COS-7, HEK293, BHK21, CHO, BSC-1, Hep G2, 653, SP2/0, 293, HeLa ili ćelijske linije mijeloma ili limfoma, ili pak bilo koju vrstu ćelija koje su iz ovih linija izvedene, imortalizovane ili transformisane.
  9. 9. <!--[endif]-->Postupak za proizvodnju najmanje jednog anti-IL-6 antitela koji obuhvata prevođenje molekula nukleinske kiseline prema patentnom zahtevu 5 u in vitro, in vivo ili in situ uslovima i u sistemima koji su različiti od čovečijeg, i to tako da se anti-IL-6 antitelo sintetiše u količini koja se može detektovati ili pak koja je dovoljna da se antitelo iz nje može izdvojiti.
  10. <!--[if !supportLists]-->10. <!--[endif]-->Preparat koji sadrži najmanje jedno od navedenih anti-IL-6 antitela prema bilo kom od patentnih zahteva od 1 do 4 i najmanje jedan farmaceutski prihvatljiv nosač ili razblaživač.
  11. <!--[if !supportLists]-->11. <!--[endif]-->Preparat prema patentnom zahtevu 10 koji dalje sadrži najmanje jedno jedinjenje ili polipeptid izabran iz grupe koju čine detektabilan obeleživač ili reporter-molekul, antagonista TNF, anti-infektivni lek, lek sa dejstvom na kardiovaskularni (KV) sistem, lek sa dejstvom na centralni nervni sistem (CNS), lek sa dejstvom na autonomni nervni sistem (ANS), lek sa dejstvom na respiratorni trakt, lek sa dejstvom na gastrointestinalni (GI) trakt, hormonski lek, lek koji deluje na održavanje balansa tečnosti ili elektrolita, hematološki lek, antineoplastični, imunomodulatorni lek, lek sa oftamološkim, otičkim ili nazanlim dejstvom, lek za topikalnu primenu, nutriticionistički lek, citokin ili antagonist citokina.
  12. <!--[if !supportLists]-->12. <!--[endif]-->Preparat koji sadrži najmanje jedno od navedenih anti-IL-6 antitela prema bilo kom od patentnih zahteva od 1 do 4 za upotrebu u terapiji.
  13. <!--[if !supportLists]-->13. <!--[endif]-->Antitelo prema bilo kom od patentnih zahteva od 1 do 4 za upotrebu u postupku dijagnoze ili tretmana stanja koje je prati povećana sinteza IL-6, a u ćeliji, tkivu, organu ili životinji, naznačeno time, što je navedeno stanje koje prati povećana proizvodnja IL-6 izabrano iz grupe koju čine gojaznost, oboljenje u čijoj osnovi je poremećaj imunog sistema, kardiovaskularno oboljenje, infektivno oboljenje ili maligna bolesti i neurološko oboljenje.
  14. <!--[if !supportLists]-->14. <!--[endif]-->Antitelo prema patentnom zahtevu 13, naznačeno time, što je stanje koje prati povećana sinteza IL-6 izabrano iz grupe koju čine reumatoidni artritis, osteoartritis, osteoliza, aseptičano popuštanje funkcije ortopedskih implantata, sistemski lupus eritematozus, kutani lupus erithematosus, lupus nefritis, dijabetes melitus tipa 2, hronična opstruktivna bolest pluća i karcinom renalnih ćelija.
  15. <!--[if !supportLists]-->15. <!--[endif]-->Antitelo prema patentnom zahtevu 13, naznačeno time, što navedena efetkivna količina antitela iznosi od oko 0,001-50 mg/kilogramu za navedene ćelije, tkivo, organ ili životinjski organizam.
  16. <!--[if !supportLists]-->16. <!--[endif]-->Antitelo prema patentnom zahtevu 13, naznačeno time, što se dovodi u kontakt odnosno primenjuje na najmanje jedan od načina koji je izabran iz grupe koju čine parenteralna, subkutana, intramuskularna, intravenozna, intraartikularna, intrabronhijalna, intraabdominalna, intrakapsularna, intrahrskavična, intrakavitalna, intrakomorna, intracerebelarna, intracerebroventrikularna, intrakolična, intracervikalna, intragastrična, intrahepatična, intramiokardna, intraostealna, intrapelvična, intraperikardijalna, intraperitonealna, intrapleuralna, intraprostatična, intrapulmonalna, intrarektalna, intrarenalna, intraretinalna, intraspinalna, intrasinovijalna, intratorakalna, intrauterina, intravezikularna, intralezijska, bolusna, vaginalna, rektalna, bukalna, sublingvalna, intranazalna i transdermalna primena.
  17. <!--[if !supportLists]-->17. <!--[endif]-->Antitelo prema patentnom zahtevu 13 i dalje njegova primena pre, istovremeno ili nakon navedenih načina dovođenja u kontakt ondosno primene, a sa najmanje još jednim preparatom koji sadrži efektivnu količinu najmanje jednog jedinjenja ili polipeptida izabranog iz grupe koju čine obeleživač ili reporter-molekul koji se može detektovati, antagonista TNF, anti-infektivni lek, lek sa dejstvom na kardiovaskularni (KV) sistem, lek sa dejstvom na centralni nervni sistem (CNS), lek sa dejstvom na autonomni nervni sistem (ANS), lek sa dejstvom na respiratorni trakt, lek sa dejstvom na gastrointestinalni (GI) trakt, hormonski lek, lek koji deluje na održavanje balansa tečnosti ili elektrolita, hematološki lek, antineoplastični, imunomodulatorni lek, lek sa oftamološkim, otičkim ili nazanlim dejstvom, lek za topikalnu primenu, nutriticionistički lek, citokin ili antagonist citokina.
  18. <!--[if !supportLists]-->18. <!--[endif]-->Medicinsko sredstvo koje sadrži anti-IL-6 antitelo prema bilo kom od patentnih zahteva od 1 do 4, naznačeno time, što je navedeni uređaj pogodan za dovođenje u kontakt odnosno primenu navedenog anti-IL-6 antitela na najmanje jedan od načina koji je izabran iz grupe koju čine parenteralna, subkutana, intramuskularna, intravenozna, intraartikularna, intrabronhijalna, intraabdominalna, intrakapsularna, intrahrskavična, intrakavitalna, intrakomorna, intracerebelarna, intracerebroventrikularna, intrakolična, intracervikalna, intragastrična, intrahepatična, intramiokardna, intraostealna, intrapelvična, intraperikardijalna, intraperitonealna, intrapleuralna, intraprostatična, intrapulmonalna, intrarektalna, intrarenalna, intraretinalna, intraspinalna, intrasinovijalna, intratorakalna, intrauterina, Intravezikularna, intralezijska, bolusna, vaginalna, rektalna, bukalna, sublingvalna, intranazalna i transdermalna primena.
  19. <!--[if !supportLists]-->19. <!--[endif]-->Gotov proizvod za farmaceutsku ili dijagnostičku upotrebu kod ljudi, naznačen time, što sadrži ambalažu i odgovarajuće pakovanje napunjeno rastvorom ili liofiliziranim anti-IL-6 antitelom prema bilo kom od patentnih zahteva od 1 do 4.
  20. 20. <!--[endif]-->Proizvod prema patentnom Patentnom zahtevu 19, naznačen time, što navedena posuda označava komponentu uređaja ili sistema za parenteralnu, subkutanu, intramuskularnu, intravenoznu, intraartikularnu, intrabronhijalnu, intraabdominalnu, intrakapsularnu, intrahrskavičnu, intrakavitalnu, intrakomornu, intracerebelarnu, intracerebroventrikularnu, intrakoličnu, intracervikalnu, intragastričnu, intrahepatičnu, intramiokardnu, intraostealnu, intrapelvičnu, intraperikardijalnu, intraperitonealnu, intrapleuralnu, intraprostatičnu, intrapulmonalnu, intrarektalnu, intrarenalnu, intraretinalnu, intraspinalnu, intrasinovijalnu, intratorakalnu, intrauterinu, intravezikularnu, intralezijsku, bolusnu, vaginalnu, rektalnu, bukalnu, sublingvalnu, intranazalnu i transdermalnu isporuku lekova.
    <!--[if !supportLists]-->21. <!--[endif]-->Izolovano anti-IL-6 antitelo prema patentnom zahtevu 1 koje sadrži varijabilni region lakog lanca sa amnokiselinskom sekvencom koju kodira jedna od nukleotidnih sekvenci iz grupe koju čine sekvence označene kao SEQ ID NO: 98, 102, 117, 121, 125 i 129, dok je aminokiselinska sekvenca varijabilnog lanca teškog kodirana jednom od nukleotidnih sekvenci iz grupe koju čine sekvence označene kao SEQ ID NO: 100, 104, 119, 123, 127 i 131.
MEP-2015-100A 2005-04-29 2006-04-28 Anti-il-6 antitela, preparati, postupci pripreme i upotrebe ME02185B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67649805P 2005-04-29 2005-04-29
US67731905P 2005-05-03 2005-05-03
EP06751915.7A EP1874351B1 (en) 2005-04-29 2006-04-28 Anti-il-6 antibodies, compositions, methods and uses
PCT/US2006/016457 WO2006119115A2 (en) 2005-04-29 2006-04-28 Anti-il-6 antibodies, compositions, methods and uses

Publications (1)

Publication Number Publication Date
ME02185B true ME02185B (me) 2016-02-20

Family

ID=37308556

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-100A ME02185B (me) 2005-04-29 2006-04-28 Anti-il-6 antitela, preparati, postupci pripreme i upotrebe

Country Status (37)

Country Link
US (11) US7560112B2 (me)
EP (3) EP1874351B1 (me)
JP (4) JP4763043B2 (me)
KR (1) KR101340950B1 (me)
CN (2) CN101415819B (me)
AR (1) AR053370A1 (me)
AU (1) AU2006242347B2 (me)
BR (1) BRPI0609869B1 (me)
CA (1) CA2606348C (me)
CR (1) CR9551A (me)
CY (1) CY1120739T1 (me)
DK (2) DK1874351T3 (me)
EA (1) EA015262B1 (me)
EC (1) ECSP077888A (me)
ES (2) ES2676732T3 (me)
HN (1) HN2006016512A (me)
HR (2) HRP20150740T1 (me)
HU (2) HUE039116T2 (me)
IL (3) IL186965A0 (me)
JO (1) JO3058B1 (me)
LT (1) LT2842968T (me)
ME (1) ME02185B (me)
MY (2) MY142835A (me)
NI (1) NI200700278A (me)
NO (1) NO342898B1 (me)
NZ (3) NZ589820A (me)
PA (1) PA8672101A1 (me)
PE (1) PE20061324A1 (me)
PL (2) PL2842968T3 (me)
PT (2) PT2842968T (me)
RS (2) RS57474B1 (me)
SI (2) SI2842968T1 (me)
SV (1) SV2006002513A (me)
TR (1) TR201809676T4 (me)
TW (1) TWI445546B (me)
WO (1) WO2006119115A2 (me)
ZA (1) ZA200710264B (me)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP1774017B1 (en) 2004-07-26 2013-05-15 Pfenex Inc. Process for improved protein expression by strain engineering
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
AU2006300234B2 (en) 2005-10-14 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
CN101356194B (zh) 2005-12-09 2013-06-12 Ucb医药有限公司 对人il-6具有特异性的抗体分子
AR057227A1 (es) * 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
EA200870130A1 (ru) * 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
EP3135298B1 (en) 2006-01-27 2018-06-06 Keio University Therapeutic agents for diseases involving choroidal neovascularization
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2025346B1 (en) 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
CN101421411B (zh) 2006-04-13 2015-06-03 中外制药株式会社 牛磺酸转运蛋白基因
CN101600793B (zh) * 2006-05-19 2013-06-26 奥尔德生物制药公司 用于获得抗原特异性b细胞的克隆群体的培养方法
CA2657581A1 (en) * 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
AU2007282023B2 (en) * 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US20080081041A1 (en) * 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
WO2008114673A1 (ja) 2007-03-15 2008-09-25 Chugai Seiyaku Kabushiki Kaisha ポリペプチドの製造方法
US9394571B2 (en) 2007-04-27 2016-07-19 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
CN101754772B (zh) * 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
MX2009013410A (es) 2007-06-08 2010-03-22 Biogen Idec Inc Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
EA201000219A1 (ru) * 2007-07-17 2010-12-30 Комбинейторкс, Инкорпорейтед Способ и композиция для лечения в-клеточных пролиферативных нарушений
WO2009011897A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
EP3246045B1 (en) * 2007-07-26 2025-09-03 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
EP2182810B1 (en) 2007-08-03 2017-11-08 Nucitec S.A. de C.V. Compositions and methods for treatment and prevention of osteoarthritis
ES2591284T3 (es) 2007-08-07 2016-11-25 Chugai Seiyaku Kabushiki Kaisha Método para la producción de proteínas heterogéneas
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP3415529B1 (en) 2007-09-26 2020-11-04 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
WO2009051109A1 (ja) 2007-10-15 2009-04-23 Chugai Seiyaku Kabushiki Kaisha 異種タンパク質を高生産する細胞の作製方法
AU2008314973C1 (en) * 2007-10-24 2014-05-08 Chugai Seiyaku Kabushiki Kaisha A cell for use in production of heteroproteins and production method using the same
EP2275443B1 (en) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2724279C (en) 2008-05-13 2017-03-07 Novimmune S.A. Anti-il-6/il-6r antibodies and methods of use thereof
US8277804B2 (en) * 2008-05-21 2012-10-02 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR20110094307A (ko) * 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. 인간화된 항-ｉｌ-6 항체
MX2011005411A (es) * 2008-11-25 2011-06-16 Alder Biopharmaceuticals Inc Anticuerpos de il-6 y uso de los mismos.
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8337847B2 (en) * 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CA2749200A1 (en) * 2009-01-29 2010-08-05 Michael Bowen Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US8741601B2 (en) 2009-04-22 2014-06-03 Chugai Seiyaku Kabushiki Kaisha Method for producing a cell capable of high-yield production of heteroproteins
TW201600110A (zh) * 2009-07-31 2016-01-01 Shin Maeda 癌之轉移抑制劑
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
US20130149312A1 (en) * 2010-04-16 2013-06-13 Mcmaster University Compositions and methods for treating copd exacerbation
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
US8524215B2 (en) 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
CN101993152B (zh) * 2010-09-21 2012-06-20 浙江大学 一种增强油脂降解菌降解能力的激活剂及其用途和使用方法
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
MX344595B (es) 2010-12-31 2016-12-20 Bioatla Llc Humanizacion rapida de anticuerpos.
CN108220297A (zh) 2011-03-09 2018-06-29 细胞信号科技公司 用于生成单克隆抗体的方法和试剂
CA2853112C (en) 2011-10-25 2018-08-21 Onclave Therapeutics Limited Antibody formulations and methods
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
TWI500629B (zh) * 2012-10-22 2015-09-21 Fountain Biopharma Inc 介白素－６抗體及其用途
CN104768578A (zh) * 2012-10-25 2015-07-08 米迪缪尼有限公司 稳定的低粘度抗体配制品
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
RU2545724C1 (ru) * 2013-10-08 2015-04-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ лечения трофических язв и длительно незаживающих гнойных ран
CA2926087C (en) * 2013-10-10 2023-03-14 Beth Israel Deaconess Medical Center, Inc. Tm4sf1 binding proteins and methods of using same
US8916341B1 (en) * 2013-11-04 2014-12-23 Allied Innovative Systems, Llc Methods for improving analyte detection using photochemical reactions
RU2550262C1 (ru) * 2014-02-28 2015-05-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CN106794363A (zh) * 2014-08-04 2017-05-31 法布里齐奥·德西尔韦斯特里 在单一丸剂/片剂/胶囊中米诺环素、氟康唑和阿托伐他汀在治疗多发性硬化中的用途
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
TWI873632B (zh) 2015-02-27 2025-02-21 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
PL3299810T3 (pl) 2015-05-19 2021-12-13 National Center Of Neurology And Psychiatry Sposób określania zastosowania nowej terapii u pacjentów ze stwardnieniem rozsianym (sm)
CA3119498A1 (en) 2015-07-31 2017-02-09 Medimmune Limited Methods for treating hepcidin-mediated disorders
KR20250008141A (ko) 2015-08-07 2025-01-14 이미지냅 인코포레이티드 분자를 표적화하기 위한 항원 결합 구조체
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US20170291942A1 (en) * 2016-04-07 2017-10-12 Janssen Biotech, Inc. Treatment of Depression Using Agents that Block Binding of IL-6 to IL-6 Receptor
AU2017261292B2 (en) * 2016-05-05 2024-06-06 The Trustees Of The University Of Pennsylvania DNA monoclonal antibodies targeting IL-6 and CD126
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
US12071476B2 (en) * 2018-03-02 2024-08-27 Kodiak Sciences Inc. IL-6 antibodies and fusion constructs and conjugates thereof
CN108588030B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
EP3817772A4 (en) 2018-06-08 2022-03-16 Imaginab, Inc. BINDING CONSTRUCTS OF ANTIGEN TO CD4
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN109946129A (zh) * 2019-03-12 2019-06-28 江苏中济万泰生物医药有限公司 五分类血细胞分析仪用质控品制备方法
WO2020213665A1 (ja) 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
EP4631523A3 (en) 2019-05-01 2025-12-31 Novo Nordisk A/S ANTI-IL-6 ANTIBODY FORMULATION
EP3986481A2 (en) 2019-06-20 2022-04-27 Takeda Pharmaceutical Company Limited Method of treatment with viral-based gene therapy
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021119669A1 (en) * 2019-12-12 2021-06-17 Loma Linda University Pathology Medical Group, Inc. Methods and compositions for treatment of acute myeloid leukemia
US20220017614A1 (en) * 2020-03-31 2022-01-20 Janssen Biotech, Inc. Anti-IL6 Agent for Treating Coronavirus Infection
WO2021236840A1 (en) * 2020-05-20 2021-11-25 The Regents Of The University Of California Rapid index for sab mortality kinetics ("risk") test
TWI872251B (zh) 2020-05-29 2025-02-11 日商中外製藥股份有限公司 含有抗體製劑
RU2745814C1 (ru) * 2020-06-05 2021-04-01 Закрытое Акционерное Общество "Биокад" Водная фармацевтическая композиция левилимаба и ее применение
WO2022005321A1 (en) * 2020-06-29 2022-01-06 Federal State Budgetary Institution Scientific center of biomedical technologies of Federal Medical and Biological Agency Inhaled tocilizumab for treating interleukin-6 related respiratory diseases
JP2024504614A (ja) * 2021-01-14 2024-02-01 トランスレイト バイオ， インコーポレイテッド ｍＲＮＡがコードする抗体を送達する方法および組成物
CN113409232B (zh) * 2021-06-16 2023-11-10 吉林大学 基于响尾蛇视觉成像的仿生假彩色图像融合模型及方法
CN113552116B (zh) * 2021-07-14 2023-08-18 四川农业大学 基于Ag@UiO-66-NH2/CsPbBr3的电致化学发光分子印迹传感器及应用
CN117949646B (zh) * 2023-12-31 2025-03-07 深圳市新产业生物医学工程股份有限公司 试剂组合以及免离心的全血中目标免疫抑制剂的检测方法

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US5326859A (en) * 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US5554513A (en) * 1979-11-21 1996-09-10 Yeda Research & Development Co. Ltd. Production of recombinant human interferon-beta2
IL58765A (en) * 1979-11-21 1986-09-30 Yeda Res & Dev Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US5001116A (en) * 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3546807C2 (me) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en) 1985-05-31 1988-08-23 President And Fellows Of Harvard College Gene amplification
US4870163A (en) 1985-08-29 1989-09-26 New York Blood Center, Inc. Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de) 1986-01-15 1987-07-16 Ant Nachrichtentech Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
WO1988001213A1 (en) 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
US4795699A (en) 1987-01-14 1989-01-03 President And Fellows Of Harvard College T7 DNA polymerase
US4921794A (en) 1987-01-14 1990-05-01 President And Fellows Of Harvard College T7 DNA polymerase
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
JP2647427B2 (ja) 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4939666A (en) 1987-09-02 1990-07-03 Genex Corporation Incremental macromolecule construction methods
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en) 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5066584A (en) 1988-09-23 1991-11-19 Cetus Corporation Methods for generating single stranded dna by the polymerase chain reaction
US5091310A (en) 1988-09-23 1992-02-25 Cetus Corporation Structure-independent dna amplification by the polymerase chain reaction
US5142033A (en) 1988-09-23 1992-08-25 Hoffmann-La Roche Inc. Structure-independent DNA amplification by the polymerase chain reaction
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6682896B1 (en) * 1988-10-14 2004-01-27 Schering Aktiengesellschaft Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US4994370A (en) 1989-01-03 1991-02-19 The United States Of America As Represented By The Department Of Health And Human Services DNA amplification technique
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
EP0478627A4 (en) 1989-05-16 1992-08-19 William D. Huse Co-expression of heteromeric receptors
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
EP0399429A1 (en) 1989-05-22 1990-11-28 Toray Industries, Inc. Anti-human interleukin-6 monoclonal antibody
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
JP3443119B2 (ja) 1989-08-07 2003-09-02 ペプテック リミテッド 腫瘍壊死因子結合リガンド
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
JPH05503098A (ja) 1989-12-15 1993-05-27 カイロン　コーポレイション セプシスの処理のためのサイトカイン抗体
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5942220A (en) * 1990-03-16 1999-08-24 Chiron Corporation Inhibitor of cytokine activity and applications thereof
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
TW212184B (me) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0600866T3 (da) 1990-06-01 1998-03-09 Chiron Corp Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
US5580734A (en) 1990-07-13 1996-12-03 Transkaryotic Therapies, Inc. Method of producing a physical map contigous DNA sequences
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992005258A1 (en) 1990-09-20 1992-04-02 La Trobe University Gene encoding barley enzyme
GB9022648D0 (en) 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
WO1992014843A1 (en) 1991-02-21 1992-09-03 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
ES2134212T3 (es) * 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
JPH05304986A (ja) 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
DE69322789T2 (de) 1992-10-19 1999-07-01 Dura Pharmaceuticals, Inc., San Diego, Calif. Trockenpulverinhalator
CA2147466A1 (en) 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DE69414369T2 (de) 1993-01-19 1999-05-27 Glaxo Group Ltd., Greenford, Middlesex Aerosol-spender und verfahren zu seiner herstellung
EP1978095A1 (en) 1993-02-12 2008-10-08 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
JP3525221B2 (ja) 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤
US5770428A (en) 1993-02-17 1998-06-23 Wisconsin Alumni Research Foundation Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
US5891998A (en) * 1993-06-23 1999-04-06 Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. Interleukin-6 receptor agonists
CN1502331A (zh) 1993-07-19 2004-06-09 Ѫ�ܼ���ҩ�﹫˾ 抗血管生长组合物及使用方法
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2183268C (en) 1994-03-07 2001-05-15 Edward D. Ball Bispecific molecules having clinical utilities
US5641657A (en) * 1994-05-19 1997-06-24 Human Genome Sciences, Inc. DNA encoding an interleukin-6 splice variant
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5738931A (en) * 1994-09-16 1998-04-14 Kabushiki Kaisha Toshiba Electronic device and magnetic device
ATE552012T1 (de) * 1994-10-07 2012-04-15 Chugai Pharmaceutical Co Ltd Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
IT1274782B (it) * 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
US5549551A (en) 1994-12-22 1996-08-27 Advanced Cardiovascular Systems, Inc. Adjustable length balloon catheter
AU704723B2 (en) * 1994-12-29 1999-04-29 Chugai Seiyaku Kabushiki Kaisha Antitumor agent effect enhancer containing IL-6 antagonist
DK0811384T3 (da) * 1995-02-13 2006-10-09 Chugai Pharmaceutical Co Ltd Muskelproteinnedbrydningsinhibitor indeholdende IL-6-receptor-antistof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5656730A (en) 1995-04-07 1997-08-12 Enzon, Inc. Stabilized monomeric protein compositions
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
IT1276555B1 (it) * 1995-04-28 1997-11-03 Angeletti P Ist Richerche Bio Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
NZ324374A (en) 1996-01-03 1999-06-29 Glaxo Group Ltd Inhalation device
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
DE19624387C2 (de) 1996-06-19 1999-08-19 Hatz Motoren Kaltstartvorrichtung
US5854398A (en) * 1996-07-25 1998-12-29 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
US6461604B1 (en) * 1996-08-16 2002-10-08 Genetics Institute, Llc Crystalline IL-6 and models of the molecular structure of IL-6
ATE210682T1 (de) 1996-09-03 2001-12-15 Gsf Forschungszentrum Umwelt Zerstörung von kontaminierenden tumorzellen in stammzelltransplantaten mit bispezifischen antikörpern
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
ES2312184T3 (es) * 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
DE69813853T3 (de) 1997-09-29 2011-05-12 Novartis Ag Perforierte mikroteilchen und deren verwendung
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
AU6934600A (en) * 1999-08-27 2001-03-26 Board Of Regents, The University Of Texas System Cd40 ligand and cd40 agonist compositions and methods of use
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
WO2002034292A1 (fr) * 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
ITPD20010108A1 (it) 2001-05-08 2002-11-08 Fidia Advanced Biopolymers Srl Biomateriali polimerici elettricamente conduttori, loro processo di preparazione ed impiego nel settore biomedico sanitario.
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DE10146643C1 (de) 2001-09-21 2003-08-14 Eads Deutschland Gmbh Verfahren zur Kalibrierung der Radarsignale an den Subaperturen der Antenne eines zweikanaligen SAR/MTI Radarsystems
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
WO2003083061A2 (en) 2002-03-26 2003-10-09 Centocor, Inc. Anti-tnf antibodies, compositions, methods and uses
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
AU2003261787B2 (en) * 2002-08-30 2008-11-06 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human antihuman interleukin-6 antibody and fragment of the antibody
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005028514A1 (en) 2003-09-22 2005-03-31 Biovation Gmbh & Co. Kg. Use of a compound for reducing the biological effectiveness of il-6
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
JP5470817B2 (ja) 2008-03-10 2014-04-16 日産自動車株式会社 電池用電極およびこれを用いた電池、並びにその製造方法
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
JP6136279B2 (ja) 2013-01-15 2017-05-31 株式会社ジェイテクト 転がり軸受装置
TWI503850B (zh) 2013-03-22 2015-10-11 Polytronics Technology Corp 過電流保護元件
TWI510996B (zh) 2013-10-03 2015-12-01 Acer Inc 控制觸控面板的方法以及使用該方法的可攜式電腦
US9816280B1 (en) 2016-11-02 2017-11-14 Matthew Reitnauer Portable floor

Also Published As

Publication number Publication date
BRPI0609869A2 (pt) 2010-05-11
WO2006119115A3 (en) 2008-01-03
EP1874351A2 (en) 2008-01-09
US20170253651A1 (en) 2017-09-07
US8226611B2 (en) 2012-07-24
US20130017208A1 (en) 2013-01-17
JP2014080427A (ja) 2014-05-08
JP5940565B2 (ja) 2016-06-29
NI200700278A (es) 2013-01-29
PT1874351E (pt) 2015-06-16
US12065488B2 (en) 2024-08-20
TW200716173A (en) 2007-05-01
SI1874351T1 (sl) 2015-10-30
NZ598657A (en) 2013-06-28
TR201809676T4 (tr) 2018-07-23
CN102924596B (zh) 2016-01-20
DK1874351T3 (en) 2015-04-20
IL211133A (en) 2015-03-31
JP5898413B2 (ja) 2016-04-06
US8623362B2 (en) 2014-01-07
RS57474B1 (sr) 2018-09-28
HN2006016512A (es) 2010-06-08
EP2842968B1 (en) 2018-05-23
US20140099311A1 (en) 2014-04-10
EA200702374A1 (ru) 2008-10-30
EP3421492A1 (en) 2019-01-02
NZ589820A (en) 2012-04-27
HK1208035A1 (en) 2016-02-19
BRPI0609869B1 (pt) 2021-08-24
KR101340950B1 (ko) 2013-12-31
JO3058B1 (ar) 2017-03-15
IL211133A0 (en) 2011-04-28
AU2006242347B2 (en) 2012-07-12
US20160222104A1 (en) 2016-08-04
US20220048985A1 (en) 2022-02-17
US9631016B2 (en) 2017-04-25
ZA200710264B (en) 2010-05-26
IL211132A0 (en) 2011-04-28
USRE43672E1 (en) 2012-09-18
PL1874351T3 (pl) 2015-10-30
RS54133B1 (sr) 2015-12-31
AR053370A1 (es) 2007-05-02
PL2842968T3 (pl) 2019-05-31
ECSP077888A (es) 2008-03-26
TWI445546B (zh) 2014-07-21
CA2606348C (en) 2012-12-11
EP1874351B1 (en) 2015-04-08
CN101415819B (zh) 2012-10-10
SV2006002513A (es) 2008-12-05
PT2842968T (pt) 2018-09-28
NO20076024L (no) 2008-01-18
MY143374A (en) 2011-04-29
US8067003B2 (en) 2011-11-29
EA015262B1 (ru) 2011-06-30
NZ562771A (en) 2011-03-31
PE20061324A1 (es) 2007-01-15
US20120045453A1 (en) 2012-02-23
MY142835A (en) 2011-01-14
US20200115445A1 (en) 2020-04-16
KR20080017014A (ko) 2008-02-25
US9340613B2 (en) 2016-05-17
HUE025376T2 (en) 2016-02-29
LT2842968T (lt) 2018-09-25
NO342898B1 (no) 2018-08-27
PA8672101A1 (es) 2006-12-07
ES2676732T3 (es) 2018-07-24
CN102924596A (zh) 2013-02-13
HRP20181218T1 (hr) 2018-10-05
ES2551985T3 (es) 2015-11-24
US20110081355A1 (en) 2011-04-07
IL186965A0 (en) 2008-02-09
CR9551A (es) 2009-07-30
CA2606348A1 (en) 2006-11-09
US7560112B2 (en) 2009-07-14
JP4763043B2 (ja) 2011-08-31
SI2842968T1 (sl) 2018-10-30
HUE039116T2 (hu) 2018-12-28
AU2006242347A1 (en) 2006-11-09
JP2011201888A (ja) 2011-10-13
US7833755B2 (en) 2010-11-16
DK2842968T3 (en) 2018-08-06
HK1116398A1 (en) 2008-12-24
JP2008538931A (ja) 2008-11-13
US20090239258A1 (en) 2009-09-24
WO2006119115A2 (en) 2006-11-09
HRP20150740T1 (hr) 2015-08-14
US11180549B2 (en) 2021-11-23
CN101415819A (zh) 2009-04-22
EP1874351A4 (en) 2010-07-28
CY1120739T1 (el) 2019-12-11
EP2842968A1 (en) 2015-03-04
JP2016117769A (ja) 2016-06-30
US20060257407A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
HRP20150740T1 (hr) Anti-il-6 antitijela, sastavi, postupci i upotrebe
HRP20140982T1 (hr) Ljudska anti-il-23 antitijela, pripravci, postupci i upotrebe
CN107108711B (zh) 包含肽变异体的药物组合物及其使用方法
JP2007508011A5 (me)
RU2016142690A (ru) Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения
JP4859248B2 (ja) 可溶性Ｇタンパク質共役型レセプター（ｓＧＰＣＲ）に関する組成物および方法
AU2010292069B2 (en) Improved Pseudomonas Exotoxin A with reduced immunogenicity
ES2533464T3 (es) Anticuerpos anti-miostatina
KR101446503B1 (ko) 열 반응성 생중합체에 기초한 직접 약물 전달 시스템
KR101309948B1 (ko) 혈관 신생 억제 화합물
JP7102670B2 (ja) 抗ｐｄ‐ｌ１抗体とｉｌ‐７との融合
JP2005512522A5 (me)
HRP20170323T1 (hr) Dopunski aktivin receptor polipeptidi i njihove upotrebe
JP2012509687A5 (me)
BR112016002008B1 (pt) Anticorpos anti-cxcr4, seu uso, conjugado anticorpo-fármaco e composição farmacêutica
EA019397B1 (ru) Антигенсвязывающие белки il-17 рецептора а
CA2609349A1 (en) Anti-mcp-1 antibodies, compositions, methods and uses
JP2005507637A5 (me)
JP2006524034A5 (me)
US20200262877A1 (en) Ion channel-binding peptides and methods of use thereof
ES2359567T3 (es) Anticuerpo humanizado específico para el factor de necrosis tumoral-alfa.
KR20180137487A (ko) 재조합 폴리스타틴-fc 융합 단백질 및 듀시엔형 근이영양증 치료에서의 용도
ES2739180T3 (es) Péptido BFP 4 para promover la formación ósea o vasculogénesis, y aplicación del mismo
ES2660739T3 (es) Tratamiento de cáncer de pulmón usando el inhibidor SIS3 de Smad3
WO2025031383A1 (zh) 双功能接头化合物、抗体药物偶联物及其制备方法和应用